Abstract
The FAB group has reviewed 32 cases of promyelocytic leukemia and variant forms. By utilizing published criteria the ability to make a correct diagnosis by morphology with molecular genetic confirmation and to eliminate cases that did not have the PML/RARalpha rearrangement was excellent.
Publication types
-
Comparative Study
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Carboxylic Ester Hydrolases / analysis
-
Chromosomes, Human, Pair 11 / ultrastructure*
-
Chromosomes, Human, Pair 15 / ultrastructure*
-
Chromosomes, Human, Pair 17 / ultrastructure*
-
Cytoplasmic Granules / enzymology
-
Cytoplasmic Granules / ultrastructure*
-
Humans
-
Leukemia, Promyelocytic, Acute / diagnosis
-
Leukemia, Promyelocytic, Acute / drug therapy
-
Leukemia, Promyelocytic, Acute / genetics*
-
Leukemia, Promyelocytic, Acute / pathology
-
Neoplasm Proteins / analysis
-
Neoplasm Proteins / genetics
-
Neoplastic Stem Cells / enzymology
-
Neoplastic Stem Cells / ultrastructure*
-
Oncogene Proteins, Fusion / analysis
-
Oncogene Proteins, Fusion / genetics
-
Peroxidase / analysis
-
Staining and Labeling
-
Translocation, Genetic*
-
Tretinoin / pharmacology
-
Tretinoin / therapeutic use
Substances
-
Antineoplastic Agents
-
Neoplasm Proteins
-
Oncogene Proteins, Fusion
-
promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
-
Tretinoin
-
Peroxidase
-
Carboxylic Ester Hydrolases
-
chloroacetate esterase